Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring its successful insulin strategy. Ozempic is slated for launch within three months, with pricing to be determined by market research.

See Full Page